http://m.seekingalpha.com/news-article/8114842-salix-pharmaceuticals-to-acquire-santarus Salix, Santarus talk synergies, diversification; 2014 guidance provided Salix Pharmaceuticals' (SLXP) deal for Santarus (SNTS) creates a specialty company with 22 marketed products and very little overlap.Uceris, Glumetza, and Zegerid — which this quarter had sales of $19.6M, $45.6M, and $27.1M, respectively — should help SLXP diversify its revenue stream. In Q3, Xifaxan accounted for nearly 70% of the top-line.The companies say that post-merger, "no product is expected to account for more than 50% of the combined company's revenue."Combined company Q3 results: Revenue of $1.348B and adjusted EBITDA of $537M.SLXP expects "revenue synergies from the increased number of sales representatives in GI and the expanded presence in primary care."FY14 combined company outlook: Adjusted EPS of $5.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.